Lexaria Bioscience Corp is a healthcare company. The Company is primarily engaged in developing drug delivery technology, DehydraTECH, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH with cannabinoids and nicotine has the ability to increase bio-absorption and mask unwanted tastes. The Company also intends to evaluate its DehydraTECH for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Number of employees : 4 people.